Global Stargardts Treatment Market, By Drug Type (Emixustat, LBS-008), Diagnosis (Visual Field Testing, Colour Testing, Fundus Photo, Electroretinography (ERG), Optical Coherence Tomography (OCT), Others), Treatment (Dark Sunglasses, Gene Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Stargardts Treatment Market Analysis and Size
The global stargardts treatment market is expected to witness significant growth during the forecast period. Several market players are focusing on numerous growth plans such as agreements and acquisitions, to accelerate the development of treatment for Stargardt disease, that is projected to boost the market growth during the forecast period. The incidence for the disease is low, about 1 in 8,000-10,000 people worldwide, as stated by National Eye Institute in April 2015. To date, there is no treatment available, though multiple therapies are in pipeline.
Data Bridge Market Research analyses a growth rate in the global stargardts treatment market in the forecast period 2022-2029. The expected CAGR of global stargardts treatment market is tend to be around 30% in the mentioned forecast period. The market was valued at USD 165.38 million in 2021, and it would grow upto USD 1349.06 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Stargardts Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Emixustat, LBS-008), Diagnosis (Visual Field Testing, Colour Testing, Fundus Photo, Electroretinography (ERG), Optical Coherence Tomography (OCT), Others), Treatment (Dark Sunglasses, Gene Therapy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
American Macular Degeneration Foundation (U.S.), Royal National Institute of Blind People (U.K.), Kubota Pharmaceutical Holdings Co., Ltd (U.S), IVERIC bio, Inc (U.S.), Sanofi (France), Alkeus Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), reVision Therapeutics, Inc. (India), Lin BioScience, Inc. (Taiwan), Biogen (U.K), F. Hoffmann-La Roche AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Stargardts disease is an inherited genetic disorder of the retina. It majorly affects the macula area of the retina responsible for the eye's sharp and central vision. The disease generally causes vision loss during childhood or adolescence age. The vision loss because of the abnormal accumulation of lipofuscin, which is a fatty yellow pigment present in the cells of the macula. Patients suffering from stargardts disease may have a problem with the color vision or night vision.
Global Stargardts Treatment Market Dynamics
Drivers
- Increase in Healthcare Expenditure
There has been increasing healthcare expenditure is boosting the growth of the market. For instance, Foundation Fighting Blindness Clinical Research Institute is completing a $6 million natural history study for people who are affected by Stargardt disease known as ProgSTAR. The study has enrolled 365 patients in 10 international clinical centers. This boost the market growth.
- Robust pipeline for stargardt disease therapeutics
Approval of numerous therapies that are currently in pipeline is projected to boost the market growth during the forecast period. For instance, in November 2017, Nightstar Therapeutics, which is a subsidiary of Biogen Inc., expanded its pipeline with gene therapy program for Stargardt disease treatment. Furthermore, Biogen Inc. acquired Nightstar Therapeutics in March 2019 to establish a clinical pipeline of gene therapy candidate for ophthalmology.
Opportunities
- Increased Strategic Agreements
Market players are focusing on numerous inorganic growth strategies such as agreements and acquisitions to increase the development of treatment for stargardt disease which is expected to boost the growth of the global stargardt disease therapeutics market during the forecast period. For instance, On January 11, 2021, Aker BioMarine, a fishing and biotech company, entered into an agreement with Dr. Michael Davidson to develop pharmaceutical therapies for diseases associated with brain and eye such as Alzheimer’s Disease, dry age-related macular degeneration, and Stargardt’s juvenile blindness, by using LYSOVETA, which is a process established by the biotech company, Aker BioMarine for production of lysophosphatidylcholine (LPC)-bound EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid) from krill.
- Increasing Demand for Retail Pharmacies
The rise in the number of stargardts therapeutics delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professionals who cannot treat patients with appropriate eye lubricants could curb the growth of the global stargardts treatment market during a forecast period.
- Unavailability of Stargardts Treatment
The major factor that impede growth of the global stargardt therapeutics market include unavailability of alternatives to restore vision in patients with stargardt disease.
This global stargardts treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global stargardts treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Stargardts Treatment Market
Market players operating in the global stargardt therapeutics market are facing main challenges due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations because of the irregularities in transportation facility. Furthermore, distributors of products are experiencing irregular demand for products from the retailers because of the growing patient population suffering from COVID-19 and other life threatening disorders. Hereafter, all these changes are impacting the stargardts treatment market significantly.
Global Stargardts Treatment Market Scope
The global stargardts treatment market is segmented on the basis of drug type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Emixustat
- LBS-008
Diagnosis
- Visual Field Testing
- Colour Testing
- Fundus Photo
- Electroretinography (ERG)
- Optical Coherence Tomography (OCT)
- Others
Treatment
- Dark Sunglasses
- Gene Therapy
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Stargardts Treatment Market Regional Analysis/Insights
The global stargardts treatment market is analyzed and market size insights and trends are provided by drug type, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global stargardts treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global stargardts treatment market throughout the forecasted period due to increased ophthalmic surgeries.
North America dominates the market due to the presence of key manufacturers of the product, high research and development, and healthcare expenditure and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Stargardts Treatment Market Share Analysis
The global stargardts treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global stargardts treatment market
Key players operating in the global stargardts treatment market include:
- American Macular Degeneration Foundation (U.S.)
- Royal National Institute of Blind People (U.K.)
- Kubota Pharmaceutical Holdings Co., Ltd (U.S)
- IVERIC bio, Inc (U.S.)
- Sanofi (France)
- Alkeus Pharmaceuticals (U.S.)
- Astellas Pharma Inc. (Japan)
- reVision Therapeutics, Inc. (India)
- Lin BioScience, Inc. (Taiwan)
- Biogen (U.K)
- F. Hoffmann-La Roche AG (Switzerland)
SKU-